Visualization of Eluvia Drug-Eluting Stent, from side close-up.
Vascular Surgery / Drug Eluting Therapies / Eluvia DES

 

A bold step forward.

Boston Scientific is committed to advancing science in the fight against PAD by boldly innovating with next-generation, drug-eluting technology. Backed by a Level‑1 Randomized Controlled Trial, our exceptional results put the power of choice in the hands of those who make it happen. Together, we can save more limbs and help more people walk without pain.

Woman standing in house doorway, holding handle of half-opened storm door.



BOLD CLINICAL TRIALS

One DES head-to-head trial.
Zero doubt.

Bold is being the first company to conduct Level-1 head-to-head comparative effectiveness trials directly comparing drug-eluting technologies. Regardless of patient or lesion complexity, Eluvia DES has durable and consistent results. See how it can make a difference in the fight against PAD.
Eluvia DES Clinical Trial ›
Visualization of Eluvia Drug-Eluting Stent, looking into the stent close-up.

NEXT-GENERATION TECHNOLOGY

Built for sustained drug release and efficient drug transfer.

Only the Eluvia™ Drug-Eluting Stent offers sustained drug release to match the restenotic process in the SFA, with the lowest drug-dose2 delivered by the most proven polymer.
Eluvia Drug-Eluting Stent ›

 

Clinical Highlights

 

Exceptional outcomes vs. Zilver™ PTX™

Eluvia DES demonstrated a statistically significant difference in primary patency versus Zilver PTX3 and achieved the highest primary patency reported in any SFA DE Pivotal Trial at 1-Year4.

IMPERIAL Trial
Primary patency rates showing Eluvia with 92.1% and Zilver PTX with 81.8%.
*Kaplan Meier Estimate; Primary patency as determined by duplex ultrasound (DUS) Peak Systolic Velocity Ratio (PSVR) is ≤ 2.4 at the 1-Year follow-up visit, in the absence of clinically-driven TLR or bypass of the target lesion.
**Log-rank p-value compares the entire K-M curves from time zero to full 1-Year follow-up window.
1. 92.1% K-M Primary Patency. 1-Year Results published in The Lancet. https://doi.org/10.1016/S0140-6736(18)32262-1.
2. Based on drug dose data from Eluvia DES, Lutonix 018 DCB, Lutonix 035 DCB, Stellarex 035 DCB and Ranger DCB Instructions for Use.
3. Kaplan-Meier Primary Patency Estimate through 1-Year (including follow-up window) was statistically significant with a p-value of 0.0094.
4. Based on 1-Year Kaplan-Meier estimates reported for IMPERIAL, RANGER II SFA, IN.PACT SFA, ILLUMENATE, LEVANT II and Primary Randomization for Zilver PTX RCT.
Legs and feet of patient sitting on bed with hands on lap.

RESTENOSIS REPLACEMENT PROGRAM

Standing together.

The Bold Step Program is a statement of our confidence in the efficacy of our drug-eluting products. The program offers an Eluvia DES or Ranger DCB at no additional charge if a patient requires reintervention within the first year due to restenosis. 
Background image of surgical area and healthcare providers' hands.

Explore DE Resources

Get physician perspectives, clinical data sheets and other resources about drug-eluting innovations.

Explore Resources ›
Background image of healthcare providers' hands using medical equipment.

Stay Up to Date

Receive emails about the latest drug-eluting technology news, innovations and events in your area.

Sign Up Today ›
take the fight to pad
Top